Characterization and long-term persistence of immune response following two doses of an AS03A-adjuvanted H1N1 influenza vaccine in healthy Japanese adults

@article{Ikematsu2012CharacterizationAL,
  title={Characterization and long-term persistence of immune response following two doses of an AS03A-adjuvanted H1N1 influenza vaccine in healthy Japanese adults},
  author={H. Ikematsu and H. Nagai and M. Kawashima and Y. Kawakami and Kazuyoshi Tenjinbaru and P. Li and Karl Walravens and P. Gillard and F. Roman},
  journal={Human Vaccines & Immunotherapeutics},
  year={2012},
  volume={8},
  pages={260 - 266}
}
  • H. Ikematsu, H. Nagai, +6 authors F. Roman
  • Published 2012
  • Biology, Medicine
  • Human Vaccines & Immunotherapeutics
  • Background Long-term persistence of immune response and safety of two doses of an A/California/07/2009 H1N1 pandemic influenza vaccine adjuvanted with AS03 (an α-tocopherol oil-in-water emulsion-based Adjuvant System) administered 21 d apart was evaluated in Japanese adults [NCT00989612]. Methods One-hundred healthy subjects aged 20−64 y (stratified [1:1] into two age strata 20−40 y and 41−64 y) received 21 d apart, two doses of AS03-adjuvanted 3.75µg haemagglutinin (HA) H1N1 2009 vaccine… CONTINUE READING
    13 Citations
    Long-term immunogenicity of two doses of 2009 A/H1N1v vaccine with and without AS03A adjuvant in HIV-1-infected adults
    • 19
    High Level Antibody Avidity is Achieved in HIV-Seropositive Recipients of an Inactivated Split Adjuvanted (AS03A) Influenza Vaccine
    • 6
    Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis
    • 39
    • Highly Influenced
    Systems biology of vaccination in the elderly.
    • 25

    References

    SHOWING 1-10 OF 35 REFERENCES
    An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers.
    • 59
    Ten Years of Experience with the Trivalent Split-Influenza Vaccine, Fluarix™
    • 65
    Immunogenicity and safety of a novel AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in adults in Japan
    • 19